As TRAIL has recently been shown to induce apoptosis effectively in tumour cells (Ashkenazi et al, 1999; Walczak et al, 1999; Dejosez et al, 2000; Nagane et al, 2000; Walczak and Krammer, 2000) but not in normal cells (Walczak et al, 1999; Kim et al, 2001b), this death ligand could be used in combination with IR in anticancer treatment. This evidence concerns the gene TNFSF10 and neoplasm.